Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available.

Foltz L, Pica GM, Zerazhi H, Van Droogenbroeck J, Visanica S, Báez de la Fuente E, Leber B, de Almeida AM, Ranta D, Kiladjian JJ, Chrit L, Kandra A, Morando J, Devos T.

Leuk Lymphoma. 2019 Jul 30:1-10. doi: 10.1080/10428194.2019.1636985. [Epub ahead of print]

PMID:
31359808
2.

Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.

Mora B, Rumi E, Guglielmelli P, Barraco D, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Pietra D, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Giorgino T, Passamonti F.

Cancer Med. 2019 Aug;8(9):4089-4092. doi: 10.1002/cam4.2107. Epub 2019 Jun 7.

3.

Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium.

Devos T, Verhoef G, Steel E, Mazure D, Lewalle P, Bron D, Berneman Z, Benghiat FS, Mineur P, Theunissen K, Zachée P, Doyen C, Put N, Lejeune M, Van Eygen K, Havelange V, Reusens M, Pluymers W, Peeters K.

Acta Haematol. 2019 Jun 4:1-11. doi: 10.1159/000499329. [Epub ahead of print]

PMID:
31163431
4.

Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis.

Demuynck T, Verhoef G, Delforge M, Vandenberghe P, Devos T.

Ann Hematol. 2019 Jun;98(6):1421-1426. doi: 10.1007/s00277-019-03654-6. Epub 2019 Mar 27.

PMID:
30919072
5.

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.

Barraco D, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Merli M, Pietra D, Barbui T, Rotunno G, Cazzola M, Giorgino T, Vannucchi AM, Passamonti F.

Blood Cancer J. 2018 Sep 21;8(10):89. doi: 10.1038/s41408-018-0128-x. No abstract available.

6.

Diagnosis and management of PNH: Review and recommendations from a Belgian expert panel.

Devos T, Meers S, Boeckx N, Gothot A, Deeren D, Chatelain B, Chatelain C, Devalet B.

Eur J Haematol. 2018 Dec;101(6):737-749. doi: 10.1111/ejh.13166. Epub 2018 Oct 23. Review.

PMID:
30171728
7.

Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients.

De Roeck L, Michaux L, Debackere K, Lierman E, Vandenberghe P, Devos T.

Hematology. 2018 Dec;23(10):785-792. doi: 10.1080/10245332.2018.1498182. Epub 2018 Jul 11.

PMID:
29993347
8.

Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial.

Griesshammer M, Saydam G, Palandri F, Benevolo G, Egyed M, Callum J, Devos T, Sivgin S, Guglielmelli P, Bensasson C, Khan M, Ronco JP, Passamonti F.

Ann Hematol. 2018 Sep;97(9):1591-1600. doi: 10.1007/s00277-018-3365-y. Epub 2018 May 27.

9.

Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.

Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Pietra D, Barbui T, Rotunno G, Vannucchi AM, Passamonti F.

Leuk Res. 2018 Jun;69:100-102. doi: 10.1016/j.leukres.2018.04.012. Epub 2018 Apr 23. No abstract available.

PMID:
29734070
10.

Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.

Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Merli M, Pietra D, Casalone R, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Passamonti F.

Haematologica. 2018 Sep;103(9):e392-e394. doi: 10.3324/haematol.2017.185751. Epub 2018 Apr 5. No abstract available.

11.

Disease and treatment characteristics of polycythemia vera patients in Belgium: Results from a scientific survey.

Devos T, Beguin Y, Noens L, Van Eygen K, Zachée P, Mineur P, Knoops L, Doyen C, Theunissen K, Benghiat FS, Reusens M, Pluymers W.

Eur J Haematol. 2018 Apr;100(4):361-366. doi: 10.1111/ejh.13022. Epub 2018 Feb 7.

12.

Recommendations on the use of ruxolitinib for the treatment of myelofibrosis.

Devos T, Selleslag D, Zachée P, Benghiat FS.

Hematology. 2018 May;23(4):194-200. doi: 10.1080/10245332.2017.1385192. Epub 2017 Oct 12.

PMID:
29022420
13.

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.

Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J.

J Clin Oncol. 2017 Dec 1;35(34):3844-3850. doi: 10.1200/JCO.2017.73.4418. Epub 2017 Sep 20.

14.

Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.

van der Krogt JA, Bempt MV, Ferreiro JF, Mentens N, Jacobs K, Pluys U, Doms K, Geerdens E, Uyttebroeck A, Pierre P, Michaux L, Devos T, Vandenberghe P, Tousseyn T, Cools J, Wlodarska I.

Haematologica. 2017 Sep;102(9):1605-1616. doi: 10.3324/haematol.2016.146571. Epub 2017 Jun 28.

15.

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.

Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Caramazza D, Merli M, Pietra D, Casalone R, Rotunno G, Barbui T, Cazzola M, Vannucchi AM.

Leukemia. 2017 Dec;31(12):2726-2731. doi: 10.1038/leu.2017.169. Epub 2017 May 31.

PMID:
28561069
16.

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.

Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, McMullin MF, Ribrag V, Schiller G, Vannucchi AM, Zhou D, Reiser D, Zhong J, Gale RP.

Leukemia. 2017 May;31(5):1252. doi: 10.1038/leu.2017.2. No abstract available.

PMID:
28465517
17.

Diagnosing nocturnal paroxysmal hemoglobinuria: a single-center 4-year experience.

Mercier T, Devos T, Mukovnikova M, Boeckx N.

Int J Lab Hematol. 2017 Jun;39(3):329-336. doi: 10.1111/ijlh.12631. Epub 2017 Apr 13.

PMID:
28406545
18.

The transcription factor GATA1 regulates NBEAL2 expression through a long-distance enhancer.

Wijgaerts A, Wittevrongel C, Thys C, Devos T, Peerlinck K, Tijssen MR, Van Geet C, Freson K.

Haematologica. 2017 Apr;102(4):695-706. doi: 10.3324/haematol.2016.152777. Epub 2017 Jan 12.

19.

A haemovigilance team provides both significant financial and quality benefits in a University Hospital.

Decadt I, Costermans E, Van de Poel M, Kesteloot K, Devos T.

Transfus Apher Sci. 2017 Apr;56(2):199-205. doi: 10.1016/j.transci.2016.11.006. Epub 2016 Dec 7.

PMID:
28027853
20.

The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study.

Van Obbergh F, Knoops L, Devos T, Beguin Y, Graux C, Benghiat F, Kargar-Samani K, Bauwens D, Efira A, Dubois C, Springael C, Montfort L, Connerotte T, Capron A, Delannoy A, Wallemacq P.

Clin Biochem. 2017 May;50(7-8):452-454. doi: 10.1016/j.clinbiochem.2016.12.006. Epub 2016 Dec 22.

21.

Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.

Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, Callum J, Vannucchi AM, Sivgin S, Bensasson C, Khan M, Mounedji N, Saydam G.

Lancet Oncol. 2017 Jan;18(1):88-99. doi: 10.1016/S1470-2045(16)30558-7. Epub 2016 Dec 2.

PMID:
27916398
22.

Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients.

Passamonti F, Mora B, Giorgino T, Guglielmelli P, Cazzola M, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver R, Benevolo G, Albano F, Caramazza D, Rumi E, Merli M, Pietra D, Casalone R, Barbui T, Pieri L, Vannucchi AM.

Leukemia. 2017 Apr;31(4):970-973. doi: 10.1038/leu.2016.351. Epub 2016 Nov 25. No abstract available.

PMID:
27885272
23.

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.

Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, McMullin MF, Ribrag V, Schiller G, Vannucchi AM, Zhou D, Reiser D, Zhong J, Gale RP.

Leukemia. 2017 Apr;31(4):896-902. doi: 10.1038/leu.2016.300. Epub 2016 Oct 24. Erratum in: Leukemia. 2017 May;31(5):1252.

24.

A novel approach for BCR-ABL1 standardization to improve International Scale estimation.

Maes B, Bakkus M, Boeckx N, Boone E, Cauwelier B, Denys B, De Schouwer P, Devos T, El Housni H, Hillen F, Jacobs K, Lambert F, Louagie H, Maes MB, Meeus P, Moreau E, Nollet F, Peeters K, Saussoy P, Van Lint P, Vaerman JL, Vaeyens F, Vandepoele K, Vannuffel P, Ver Elst K, Vermeulen K, Bruyndonckx R; Belgian working group on BCR-ABL1 IS standardization.

Int J Lab Hematol. 2016 Dec;38(6):674-684. doi: 10.1111/ijlh.12556. Epub 2016 Jul 27.

PMID:
27460189
25.

Reducing implicit racial preferences: II. Intervention effectiveness across time.

Lai CK, Skinner AL, Cooley E, Murrar S, Brauer M, Devos T, Calanchini J, Xiao YJ, Pedram C, Marshburn CK, Simon S, Blanchar JC, Joy-Gaba JA, Conway J, Redford L, Klein RA, Roussos G, Schellhaas FM, Burns M, Hu X, McLean MC, Axt JR, Asgari S, Schmidt K, Rubinstein R, Marini M, Rubichi S, Shin JE, Nosek BA.

J Exp Psychol Gen. 2016 Aug;145(8):1001-16. doi: 10.1037/xge0000179. Epub 2016 Jun 16.

PMID:
27454041
26.

A surprising cause of polycythaemia.

De Maeyer NE, Van Lommel S, Devos T, Buyse B, Nackaerts K.

Thorax. 2016 Oct;71(10):967-8. doi: 10.1136/thoraxjnl-2016-208610. Epub 2016 Jul 7. No abstract available.

PMID:
27388485
27.

Validated UPLC-MS/MS Methods To Quantitate Free and Conjugated Alternaria Toxins in Commercially Available Tomato Products and Fruit and Vegetable Juices in Belgium.

Walravens J, Mikula H, Rychlik M, Asam S, Devos T, Njumbe Ediage E, Diana Di Mavungu J, Jacxsens L, Van Landschoot A, Vanhaecke L, De Saeger S.

J Agric Food Chem. 2016 Jun 22;64(24):5101-9. doi: 10.1021/acs.jafc.6b01029. Epub 2016 Jun 7.

PMID:
27180605
28.

Budd-Chiari syndrome: reassessment of a step-wise treatment strategy.

Martens P, Maleux GA, Devos T, Monbaliu D, Heye S, Verslype C, Laleman W, Cassiman D, Van der Merwe SW, Van Steenbergen W, Jochmans I, Aerts R, Pirenne J, Nevens F.

Acta Gastroenterol Belg. 2015 Jul-Sep;78(3):299-305.

PMID:
26448411
29.
30.

Lack of clinical benefit of zoledronic acid in myelofibrosis: results of a prospective multi-center phase II trial.

Delforge M, Devos T, Rowe J, Español I, Durrant ST, Raddoux J, Boogaerts M, Gramatzki M, Gunther A.

Leuk Lymphoma. 2016 Feb;57(2):470-473. doi: 10.3109/10428194.2015.1055481. Epub 2015 Jul 7. No abstract available.

PMID:
26022523
31.

Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.

Al Assaf C, Van Obbergh F, Billiet J, Lierman E, Devos T, Graux C, Hervent AS, Emmerechts J, Tousseyn T, De Paepe P, Papadopoulos P, Michaux L, Vandenberghe P.

Haematologica. 2015 Jul;100(7):893-7. doi: 10.3324/haematol.2014.118299. Epub 2015 May 1.

32.

Single and multiple dose MultiStem (multipotent adult progenitor cell) therapy prophylaxis of acute graft-versus-host disease in myeloablative allogeneic hematopoietic cell transplantation: a phase 1 trial.

Maziarz RT, Devos T, Bachier CR, Goldstein SC, Leis JF, Devine SM, Meyers G, Gajewski JL, Maertens J, Deans RJ, Van't Hof W, Lazarus HM.

Biol Blood Marrow Transplant. 2015 Apr;21(4):720-8. doi: 10.1016/j.bbmt.2014.12.025. Epub 2014 Dec 30.

33.

Myelofibrosis patients in Belgium: disease characteristics.

Devos T, Zachée P, Bron D, Noens L, Droogenbroeck JV, Mineur P, Beguin Y, Berneman Z, Benghiat FS, Kentos A, Chatelain C, Demuynck H, Lemmens J, Eygen KV, Theunissen K, Trullemans F, Pierre P, Pluymers W, Knoops L.

Acta Clin Belg. 2015 Apr;70(2):105-11. doi: 10.1179/2295333714Y.0000000097. Epub 2014 Nov 6.

34.

Shades of American Identity: Implicit Relations between Ethnic and National Identities.

Devos T, Mohamed H.

Soc Personal Psychol Compass. 2014 Nov 1;8(12):739-754. Epub 2014 Dec 7.

35.

Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany.

Adler A, Geiger S, Keil A, Bias H, Schatz P, deVos T, Dhein J, Zimmermann M, Tauber R, Wiedenmann B.

BMC Gastroenterol. 2014 Oct 17;14:183. doi: 10.1186/1471-230X-14-183.

37.

Treatment with lenalidomide (Revlimid®), cyclophosphamide (Endoxan®) and prednisone (REP) in relapsed/refractory multiple myeloma patients: results of a single centre retrospective study.

Zelis N, Devos T, Dierickx D, Janssens A, Raddoux J, Verhoef G, Delforge M.

Acta Clin Belg. 2014 Apr;69(2):98-103. doi: 10.1179/0001551214Z.00000000030. Epub 2014 Mar 4.

PMID:
24724748
38.

Long-term follow-up in a patient with the dermato-neuro syndrome treated with high-dose melphalan, thalidomide, and intravenous immunoglobulins for more than 7 years.

Devos T, Thiessen S, Cuyle PJ, Meersseman W, Delforge M.

Ann Hematol. 2014 Nov;93(11):1927-8. doi: 10.1007/s00277-014-2065-5. Epub 2014 Mar 28. No abstract available.

PMID:
24676971
39.

Screening of JAK2 V617F and MPL W515 K/L negative essential thrombocythaemia patients for mutations in SESN2, DNAJC17, ST13, TOP1MT, and NTRK1.

Al Assaf C, Lierman E, Devos T, Billiet J, Graux C, Papadopoulos P, Vandenberghe P.

Br J Haematol. 2014 Jun;165(5):734-7. doi: 10.1111/bjh.12790. Epub 2014 Feb 26. No abstract available.

40.

Overweight people have low levels of implicit weight bias, but overweight nations have high levels of implicit weight bias.

Marini M, Sriram N, Schnabel K, Maliszewski N, Devos T, Ekehammar B, Wiers R, HuaJian C, Somogyi M, Shiomura K, Schnall S, Neto F, Bar-Anan Y, Vianello M, Ayala A, Dorantes G, Park J, Kesebir S, Pereira A, Tulbure B, Ortner T, Stepanikova I, Greenwald AG, Nosek BA.

PLoS One. 2013 Dec 17;8(12):e83543. doi: 10.1371/journal.pone.0083543. eCollection 2013.

41.

A 75-year-old missionary with fever, splenomegaly and pancytopenia.

Masfrancx D, De Munter P, Devos T.

Acta Clin Belg. 2013 May-Jun;68(3):225-8.

PMID:
24156227
42.

Machine perfusion in organ transplantation: a tool for ex-vivo graft conditioning with mesenchymal stem cells?

Van Raemdonck D, Neyrinck A, Rega F, Devos T, Pirenne J.

Curr Opin Organ Transplant. 2013 Feb;18(1):24-33. doi: 10.1097/MOT.0b013e32835c494f. Review.

PMID:
23254699
43.

The use of monoclonal antibodies in immune-mediated hematologic disorders.

Dierickx D, Beke E, Devos T, Delannoy A.

Med Clin North Am. 2012 May;96(3):583-619, xi. doi: 10.1016/j.mcna.2012.04.006. Epub 2012 May 17. Review.

PMID:
22703857
44.

G-CSF stem cell mobilization in human donors induces polymorphonuclear and mononuclear myeloid-derived suppressor cells.

Luyckx A, Schouppe E, Rutgeerts O, Lenaerts C, Fevery S, Devos T, Dierickx D, Waer M, Van Ginderachter JA, Billiau AD.

Clin Immunol. 2012 Apr;143(1):83-7. doi: 10.1016/j.clim.2012.01.011. Epub 2012 Jan 30.

PMID:
22341087
45.

The psychological costs of painless but recurring experiences of racial discrimination.

Huynh QL, Devos T, Dunbar CM.

Cultur Divers Ethnic Minor Psychol. 2012 Jan;18(1):26-34. doi: 10.1037/a0026601.

46.

Subset characterization of myeloid-derived suppressor cells arising during induction of BM chimerism in mice.

Luyckx A, Schouppe E, Rutgeerts O, Lenaerts C, Koks C, Fevery S, Devos T, Dierickx D, Waer M, Van Ginderachter JA, Billiau AD.

Bone Marrow Transplant. 2012 Jul;47(7):985-92. doi: 10.1038/bmt.2011.207. Epub 2011 Oct 31.

PMID:
22041852
47.
48.

Myeloablative conditioning predisposes patients for Toxoplasma gondii reactivation after allogeneic stem cell transplantation.

Meers S, Lagrou K, Theunissen K, Dierickx D, Delforge M, Devos T, Janssens A, Meersseman W, Verhoef G, Van Eldere J, Maertens J.

Clin Infect Dis. 2010 Apr 15;50(8):1127-34. doi: 10.1086/651266.

PMID:
20218875
49.

Thrombotic microangiopathy following intestinal transplantation: a single center experience.

Dierickx D, Monbaliu D, De Rycke A, Wisanto E, Lerut E, Devos T, Meers S, Darius T, Ferdinande P, Pirenne J.

Transplant Proc. 2010 Jan-Feb;42(1):79-81. doi: 10.1016/j.transproceed.2009.12.016.

PMID:
20172285
50.

Say "adios" to the American dream? The interplay between ethnic and national identity among Latino and Caucasian Americans.

Devos T, Gavin K, Quintana FJ.

Cultur Divers Ethnic Minor Psychol. 2010 Jan;16(1):37-49. doi: 10.1037/a0015868.

Supplemental Content

Support Center